What is the recommended CJC-1295 (DAC) dosage?

CJC-1295 (DAC) dosing varies by experience level. Beginners typically start at 1000mcg weekly, moderate users at 2000mcg weekly, and aggressive protocols use 2000mcg 2x/week.

How do you reconstitute CJC-1295 (DAC)?

CJC-1295 (DAC) typically comes in 2mg or 5mg vials. Add 2mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of CJC-1295 (DAC)?

The half-life of CJC-1295 (DAC) is ~8 days. This determines how frequently you need to dose for consistent blood levels.

CJC-1295 (DAC)

Growth HormoneInjectionResearchGrade B~8 days half-life

Growth Hormone SecretagoguePerformance EnhancementBody RecompositionSleep Regulation12 weeks on / 4 weeks off

Benefits

Long-acting — only 1-2 injections per week

Sustained GH elevation for days

Promotes lean muscle growth

Enhances fat metabolism

Improves sleep quality and recovery

Half-Life

~8 days

Route

Injection

Frequency

Weekly

Vial Sizes

2mg, 5mg

BAC Water

2mL

Safety Grade

Grade B

Open CJC-1295 (DAC) Dosage Calculator

Calculate exact syringe units for your vial and dose

About CJC-1295 (DAC)

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone releasing hormone (GHRH) analog. The DAC modification allows it to bind to albumin in the blood, extending its half-life to about 8 days. This creates sustained, elevated growth hormone levels rather than natural pulsatile release. Best for those wanting steady GH elevation with minimal injection frequency.

Who Should Consider CJC-1295 (DAC)

Adults over 30 with age-related GH decline (somatopause) seeking sustained GH support
Athletes and bodybuilders wanting steady GH elevation with minimal injection frequency
Adults seeking improved body composition with once-weekly dosing convenience
Individuals with poor sleep quality and slow recovery between training sessions
Post-injury patients wanting prolonged GH-mediated tissue repair

How CJC-1295 (DAC) Works

CJC-1295 with DAC binds to the GHRH receptor on pituitary somatotroph cells to stimulate growth hormone release. The Drug Affinity Complex (DAC) contains a reactive maleimido group that forms a covalent bond with Cys34 on circulating serum albumin after injection. This bioconjugation shields the peptide from enzymatic degradation and renal clearance, extending its half-life from minutes to approximately 8 days. The result is sustained, non-pulsatile GH elevation and prolonged IGF-1 increases lasting 9-11 days after a single dose.

What to Expect

Week 1-2

Improved sleep quality and mild water retention as GH and IGF-1 levels rise. Sustained GH elevation begins within hours of first injection.

Weeks 3-4

Recovery between training sessions improves. Skin hydration and quality begin to improve. Energy and mood stabilize.

Months 2-3

Visible body composition changes — reduced abdominal fat, improved muscle fullness. Joint and connective tissue recovery accelerates.

Months 3-4

Peak anti-aging and body composition benefits. Sustained fat loss with preserved lean mass. Hair and nail growth may accelerate.

Month 5+

Benefits plateau. Cycle off for 4 weeks to restore pituitary sensitivity before restarting.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	1mg	Weekly
Moderate	2mg	Weekly
Aggressive	2mg	2x/week

Note: Long-acting GHRH analog with Drug Affinity Complex. Sustained GH elevation. Once-weekly dosing.

How to Inject CJC-1295 (DAC)

Inject subcutaneously once or twice weekly. Timing relative to meals is less critical than with short-acting GHRH analogs due to sustained release. Rotate injection sites between abdomen, thigh, and upper arm. Evening dosing may complement natural nocturnal GH secretion.

Cycling Protocol

On Period

12 weeks

Off Period

4 weeks

Cycle to maintain pituitary sensitivity. The long half-life means steady-state is reached after 2-3 injections.

Pharmacokinetics

Half-Life

192h

Bioavailability

SC: estimated 90%+ due to albumin binding preventing degradation

Tmax

2-4 hours (GH peak after SC injection)

Data Confidence

moderate

Source: Estimated t½ 5.8-8.1 days via albumin bioconjugation (Teichman et al. 2006 PMID 16352683)

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Water retention, tingling/numbness in extremities, joint pain. May cause sustained GH elevation that doesn't mimic natural pulsatile release.

Contraindications

Active cancer or history of malignancy — sustained GH elevation promotes cell proliferation
Diabetes mellitus — prolonged GH release antagonizes insulin and may worsen glycemic control
Pregnancy or breastfeeding
Active pituitary tumors or other intracranial neoplasms
Hypersensitivity to GHRH analogs or any component of the formulation
Acute critical illness — elevated GH during critical illness is associated with increased mortality

Drug Interactions

Insulin and oral hypoglycemics — sustained GH release antagonizes insulin action; frequent blood glucose monitoring required
Corticosteroids — chronic use blunts GH response and counteracts anabolic benefits
Other GH secretagogues (GHRP-2, GHRP-6, sermorelin) — additive GH release increases side effect risk; avoid stacking without medical supervision
Thyroid hormones — GH accelerates T4-to-T3 conversion; monitor thyroid function during use
Anticoagulants (warfarin, heparin) — albumin binding may theoretically alter drug displacement; monitor INR
CYP450-metabolized drugs — GH may alter hepatic clearance of CYP3A4 substrates